Form DEFA14A Fusion Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- EverCommerce names Alex Goor as new CEO, founder steps down
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight
March 19, 2024 2:40 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).
The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More
Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold
March 19, 2024 10:00 AM EDTJefferies analyst Suji Jeong downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Buy to Hold with a price target of $21.00 (from $10.00).
The analyst comments "AZN will acquire FUSN's radiopharma platform for $21/sh in cash (~$2B upfront), plus another $3/sh CVR (~$400M value) upon... More
